Facible’s Q-LAAD technology can signal the presence of a target molecule

The Q-LAAD Singularity

Unleashing Fluorogenic Aptamers

Our Q-LAAD technology uses fluorogenic-logic aptamers to signal the presence of a target molecule. Fluorogenic aptamers can be chemically synthesized enabling decreases in production time and batch-to-batch variation which allows development to be separated from production.

Unparalleled Adaptability

Q-LAAD FastTrack tests are designed to be plug-and-play, requiring minimal adaptation time associated with new test development and we can quickly design tests that detect a range of molecules.

Optimized Usability

Q-LAAD FastTrack tests can be utilized in hospitals with commercially available analyzers that fit within standard medical laboratory workflows, thus requiring minimal training or new expertise.

A New Biodiagnostic Paradigm

In addition to our revolutionary Q-LAAD test, we are developing a proprietary analyzer enabling simple plug-and-play tests that can be administered at the point of care. These point-of-use Q-LAAD tests allow us to deliver on our mission to provide lab-grade quality diagnostics to those who are in the most need regardless of geography or socioeconomic status.

Let Steve (our self-proclaimed eccentric CEO) and Travis (our self-proclaimed dashing CMO) take you through our mission, our origin story, our innovative Q-LAAD technology, and how we're using it to take the fight to the COVID-19 pandemic.

Do you have questions about Facible? Read our FAQs below

What is Q-LAAD?

Q-LAAD stands for Quantum-Logic Aptamer Analyte Detection and it is our proprietary test which we’ve been developing over the past 6 years. Q-LAAD is an antigen detection system that uses aptamer technology to reveal the presence of viral antigens.

How do Q-LAAD tests work?

Q-LAAD technology enables a fluorogenic logic aptamer to cause a dim fluorophore to become bright only when the aptamer is bound to the intended target.

How is Q-LAAD different than other biodiagnostic tests such as PCR, Isothermal Amplification, ELISA, etc.?

Q-LAAD tests differ from other testing methodologies in a few important ways:

Q-LAAD tests are sensitive enough to detect even trace amounts of a given target molecule, so there is no time-consuming amplification required to see results. Therefore, results from Q-LAAD tests are near-instantaneous.
Q-LAAD tests are specific enough to work with various types of samples and sample collection media such as blood, saliva, urine, etc.
Q-LAAD tests are much simpler and easier to use than other biodiagnostic tests which minimizes the margin for user and/or machine error.

Do Q-LAAD tests require any special, costly equipment?

No. Q-LAAD tests can be run on commercially available COMS analyzers and plate readers. We are currently working on our own point-of-care analyzer which will make Q-LAAD tests even more efficient and easy to use.

Why is Q-LAAD a better testing method for COVID-19?

Q-LAAD tests are optimal for the current COVID-19 pandemic for three key reasons

Accuracy: Q-LAAD tests meet or exceed a minimum threshold of 95% accuracy putting it on par with the most accurate (PCR) tests currently available
Speed: Q-LAAD tests routinely deliver results in less than 5 minutes (and often near instantly) without sacrificing accuracy
Throughput: Q-LAAD tests require minimal preparation and or specialized training. and can be run on a standard plate reader in minutes allowing

What are the applications for Q-LAAD tests beyond COVID-19?

COVID-19 is only the beginning. In addition to a variety of medical diagnostic tests beyond COVID-19, we are developing Q-LAAD tests for use across a wide range of industries including Agricultural, Regulatory, Pharmaceutical, and Veterinary just to name a few.

Are you guys crazy?

Nope. Not crazy. Just audacious.

The Q-LAAD Singularity

Unparalleled Adaptability

Optimized Usability

A New Biodiagnostic Paradigm

Do you have questions about Facible? Read our FAQs below

Didn't find the answer to your question? Don't hesitate to contact us.

Stay Informed.